Who Buys Gefitinib from India — 135 Importers Behind a $6.8M Market

The importers of Gefitinib from India can be categorized into several key segments:

1. Distributors: These entities purchase Gefitinib in bulk to supply to various healthcare providers, pharmacies, and hospitals within their respective countries. For instance, THE MODERN CO in Iraq, which imported Gefitinib worth $2.09 million, likely functions as a distributor, ensuring the widespread availability of the drug across the nation.

2. Hospital Groups: These are conglomerates of hospitals that procure medications directly to meet the needs of their patients. While specific hospital groups are not explicitly listed among the top buyers, it's common for such entities to engage in direct procurement to streamline their supply chains.

3. Retail Chains: Pharmacy chains that purchase Gefitinib to stock their outlets fall into this category. The data does not specify retail chains among the top buyers, but such entities play a crucial role in making medications accessible to the general public.

4. Government Procurement: This segment includes national health departments and international organizations like UNICEF and the Global Fund that procure medications for public health initiatives. The data does not explicitly mention such entities among the top buyers, but government procurement is a significant channel for distributing essential medicines.

5. Re-exporters: Companies that import Gefitinib with the intention of exporting it to other markets. For example, OOOJODAS EXPOIM in Russia, with imports totaling $0.25 million, may act as a re-exporter, distributing the drug to neighboring regions.

6. Contract Manufacturers: These are firms that import Gefitinib for the purpose of further processing or repackaging under different brand names. The data does not provide specific examples of contract manufacturers among the top buyers.

Each segment exhibits distinct purchasing behaviors. Distributors and re-exporters often place large, periodic orders to maintain adequate stock levels and meet market demand. Hospital groups and retail chains may order smaller quantities more frequently, aligning with patient needs and inventory management practices. Government procurement typically involves bulk purchases through tenders, aiming to secure medications at competitive prices for public health programs.

Understanding the import regulations for Gefitinib in the top importing countries is crucial for market entry and compliance.

The demand for Gefitinib in importing countries is primarily driven by the prevalence of non-small cell lung cancer (NSCLC), for which Gefitinib is a targeted therapy. According to the World Health Organization (WHO), lung cancer remains one of the leading causes of cancer-related deaths globally, with NSCLC accounting for approximately 85% of cases. The inclusion of Gefitinib in the WHO Essential Medicines List underscores its importance in cancer treatment protocols.

Government healthcare programs and the expansion of universal health coverage in countries like Brazil and the Philippines have facilitated greater access to essential medicines, including Gefitinib. Tender-based purchasing mechanisms are commonly employed by these governments to procure medications at competitive prices, ensuring a steady supply for public health institutions. The presence of 135 buyers across 47 countries, as per our data, indicates a broad and growing market for Gefitinib, reflecting its critical role in oncology treatment worldwide.

The importers of Gefitinib from India can be categorized into several key segments:

1. Distributors: These entities purchase Gefitinib in bulk to supply to various healthcare providers, pharmacies, and hospitals within their respective countries. For instance, THE MODERN CO in Iraq, which imported Gefitinib worth $2.09 million, likely functions as a distributor, ensuring the widespread availability of the drug across the nation.

2. Hospital Groups: These are conglomerates of hospitals that procure medications directly to meet the needs of their patients. While specific hospital groups are not explicitly listed among the top buyers, it's common for such entities to engage in direct procurement to streamline their supply chains.

3. Retail Chains: Pharmacy chains that purchase Gefitinib to stock their outlets fall into this category. The data does not specify retail chains among the top buyers, but such entities play a crucial role in making medications accessible to the general public.

4. Government Procurement: This segment includes national health departments and international organizations like UNICEF and the Global Fund that procure medications for public health initiatives. The data does not explicitly mention such entities among the top buyers, but government procurement is a significant channel for distributing essential medicines.

5. Re-exporters: Companies that import Gefitinib with the intention of exporting it to other markets. For example, OOOJODAS EXPOIM in Russia, with imports totaling $0.25 million, may act as a re-exporter, distributing the drug to neighboring regions.

6. Contract Manufacturers: These are firms that import Gefitinib for the purpose of further processing or repackaging under different brand names. The data does not provide specific examples of contract manufacturers among the top buyers.

Each segment exhibits distinct purchasing behaviors. Distributors and re-exporters often place large, periodic orders to maintain adequate stock levels and meet market demand. Hospital groups and retail chains may order smaller quantities more frequently, aligning with patient needs and inventory management practices. Government procurement typically involves bulk purchases through tenders, aiming to secure medications at competitive prices for public health programs.

Understanding the import regulations for Gefitinib in the top importing countries is crucial for market entry and compliance.

The demand for Gefitinib in importing countries is primarily driven by the prevalence of non-small cell lung cancer (NSCLC), for which Gefitinib is a targeted therapy. According to the World Health Organization (WHO), lung cancer remains one of the leading causes of cancer-related deaths globally, with NSCLC accounting for approximately 85% of cases. The inclusion of Gefitinib in the WHO Essential Medicines List underscores its importance in cancer treatment protocols.

Government healthcare programs and the expansion of universal health coverage in countries like Brazil and the Philippines have facilitated greater access to essential medicines, including Gefitinib. Tender-based purchasing mechanisms are commonly employed by these governments to procure medications at competitive prices, ensuring a steady supply for public health institutions. The presence of 135 buyers across 47 countries, as per our data, indicates a broad and growing market for Gefitinib, reflecting its critical role in oncology treatment worldwide.